Summary: On ABC Radio National’s All in the Mind podcast, MAPS Founder and Executive Director Rick Doblin, Ph.D., explains the results of MAPS’ first Phase 3 clinical trial of MDMA-assisted therapy for PTSD and outlines estimated approval timelines in the U.S. and Australia alike.
“We think before the end of 2023 we should have approval for prescription use of MDMA-assisted therapy for PTSD in the United States,” says Doblin. “The Therapeutic Goods Administration (TGA) could potentially approve MDMA in Australia before the U.S. Food and Drug Administration (FDA) does because they have a shorter timeline for review. So I think before the end of 2023, there’s a very good chance Australia will also approve prescription use of MDMA-assisted therapy for PTSD.”